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Membrane fusionWe have studied the binding and interaction of the peptide E1FP with various model membranes. E1FP is
derived from the amino acid segment 274–291 of the hepatitis C virus envelope glycoprotein E1, which was
previously proposed to host the peptide responsible for fusion to target membranes. In the present study we
addressed the changes which take place upon E1FP binding in both the peptide and the phospholipid bilayer,
respectively, through a series of complementary experiments. We show that peptide E1FP binds to and
interacts with phospholipid model membranes, modulates the polymorphic phase behavior of membrane
phospholipids, is localized in a shallow position in the membrane and interacts preferentially with
cholesterol. The capability of modifying the biophysical properties of model membranes supports its role in
HCV-mediated membrane fusion and suggests that the mechanism of membrane fusion elicited by class I
and II fusion proteins might be similar.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Hepatitis C virus (HCV) is a small, enveloped positive single-
stranded RNA virus that belongs to the genusHepacivirus in the family
Flaviviridae. HCV is an important public health problem since it is the
leading cause of acute and chronic liver disease in humans [1–3]. The
HCV genome shows a remarkable sequence variation since more than
90 genotypes distributed into six main types and subtypes have been
identiﬁed [2]. There is no vaccine to prevent HCV infection, and
current therapeutic agents, apart from being associated to different
adverse effects, have limited success against HCV [4].
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ll rights reserved.structural and non-structural proteins [5]. HCV entry into the cell is
achieved by the fusion of viral and cellular membranes. Morphogen-
esis and budding has been suggested to take place in the endoplasmic
reticulum [6]. The HCV membrane fusion process is pH-dependent,
and low endosomal pH promotes the arrangement of the HCV E1/E2
glycoproteins to its active form [7]. The variability of the HCV proteins
gives the virus the ability to escape the host's immune surveillance
system and the development of a vaccine is a difﬁcult task [8]. Finding
protein–membrane and protein–protein interaction inhibitors could
be a good strategy against HCV infection since they might prove to be
potential therapeutic agents.
The envelope transmembrane glycoproteins E1 and E2 are
anchored to the host cell-derived double-layer lipid envelope. They
are essential for entry, binding to receptors and induce fusionwith the
host-cell membrane as well as in viral particle assembly [9]. These
proteins interact with each other and assemble as non-covalent
heterodimers; their transmembrane domains (TM) play a major role
in heterodimer formation, membrane anchoring and endoplasmic
reticulum retention [10]. StudieswithHCVpp bearing functional E1 and
E2 glycoproteins have probed that HCV viral fusion is dependent on
the presence of both E1 and E2 glycoproteins [11]. The presence of
cholesterol in target membranes facilitates, but is not essential for,
HCVpp-mediated fusion [11]. E1 and E2 are class II fusion proteins with
the putative fusion peptide/peptides which is/are supposedly local-
ized in an internal sequence linked by antiparallel β-sheets [12,13].
Many aspects regarding the function and properties of both HCV E1
and E2 glycoproteins still remain unresolved; even so, the location of
the fusion peptide is controversial since several data suggest that it
could be located in either E1 or E2 or both [7,11,14–16].
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HCV E1, E2, core and p7 proteins by studying the effect of protein-
derived peptide libraries onmodelmembrane integrity [17–19]. These
results indicate the possible location of different segments in these
proteins which might be implicated in protein–lipid and protein–
protein interactions, helping us to understand the mechanisms that
underlay the interaction between viral proteins and membranes.
Proteomics computational tools located the fusion peptide in the E1
region comprised by amino acids 272 to 281. This region contains
cysteine residues and a core of aromatic and hydrophobic residues
[12]. Peptides derived from this region have signiﬁcant experimental
membranotropic leakage, hemifusion and fusion effects [19] (see
Fig. 1). Membrane fusion is a complex process that involves several
regions of the fusion proteins. The fusion proteins must bring the viral
and cellular membranes together, create membrane defects, induce
hemifusion and fusion, and formporeswithin themembranes [20–22].
In order to elucidate the nature of the interaction between phospho-
lipids and membrane proteins and in particular to understand the
structural function of the fusion peptide in E1 HCV, we have
characterized the interaction of E1FP, a peptide derived from the
amino acid sequence 274–291 of the HCV E1 glycoprotein fusion
domain, with model membranes using biophysical techniques. We
demonstrate that the E1FP peptide strongly partitions into phospho-
lipid membranes, locates in a shallow position in the membrane,
increases the dipole membrane potential, and leads to lipid mixing
depending on the cholesterol concentration in the membrane.
Furthermore, E1FP increases membrane disorder and stabilizes the
presence of non-lamellar structures, without changing the membrane
thickness signiﬁcantly. Thus, our study provides new evidence for the
functional role of this region in the membrane fusion mechanism of
HCV.Fig. 1. Hydrophobic moment (HM), hydrophobicity (H), and interfacial hydrophobicity (I) d
wheel [71]. Only positive bilayer-to-water transfer free-energy values are shown (the darker
corresponding to 18-mer peptide libraries derived from the whole HCV E1 [19] protein is a2. Materials and methods
2.1. Materials and reagents
The peptide E1FP corresponding to the sequence 274AMYVGDLCG-
SIFLVSQLFT
291
from HCV strain 1B4J (with N-terminal acetylation and C-
terminal amidation) was obtained from Genemed Synthesis, San
Antonio, Texas. The peptide E1FP was puriﬁed by reverse-phase HPLC
(Vydac C-8 column, 250×4.6 mm, ﬂow rate 1 ml/min, solvent A, 0.1%
triﬂuoroacetic acid, solvent B, 99.9 acetonitrile and 0.1% triﬂuoroacetic
acid) to better than 95% purity, and its composition andmolecular mass
were conﬁrmed by amino acid analysis andmass spectroscopy. Residual
triﬂuoroacetic acid, used both in peptide synthesis and in the high-
performance liquid chromatography mobile phase, was removed by
several lyophilisation/solubilisation cycles in 10 mM HCl [23]. Egg L-α-
phosphatidylcholine (EPC), egg L-α-phosphatidic acid (EPA), egg
sphingomyelin (ESM), bovine brain phosphatidylserine (BPS), egg L-
α-phosphatidylglycerol (EPG), cholesterol (CHOL), liver lipid extract
(LV), 1,2-dielaidoyl-sn-glycero-3-phosphoethanolamine (DEPE), and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)were obtained
from Avanti Polar Lipids (Alabaster, AL, USA). Lissamine rhodamine B
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (N-RhB-PE),
N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-
3-phosphoethanolamine (NBD-PE), ﬂuorescein-phosphatidylethanol-
amine (FPE) and 4-(2-(6-(Dioctylamino)-2-naphthalenyl) (ethenyl)-
1-(3-sulfopropyl)-pyridinium inner salt (di-8-ANEPPS) were obtained
fromMolecular Probes (Eugene, OR). 5-Carboxyﬂuorescein (CF), (>95%
by HPLC), 5-doxyl-stearic acid (5NS), 16-doxyl-stearic acid (16NS),
dehydroergosterol (ergosta-5,7,9(11),22-tetraen-3ß-ol, DHE), sodium
dithionite, deuterium oxide (99.9% by atom), Triton X-100, EDTA, and
HEPES were purchased from Sigma-Aldrich (Madrid, ES). All otheristribution, for HCV E1 envelope glycoprotein [19] assuming that it forms an α-helical
, the greater). A summary of the normalized experimental membrane rupture data (LK)
lso shown, as well as the sequence and the location of the E1FP peptide.
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Water was deionized, twice-distilled and passed through a Milli-Q
equipment (Millipore Ibérica, Madrid, ES, EU) to a resistivity better than
18MΩ cm.
2.2. Vesicle preparation
Aliquots containing the appropriate amount of lipid in chloroform/
methanol (2:1, v/v)were placed in a test tube, the solvents removed by
evaporation under a stream of O2-free nitrogen, and ﬁnally, traces of
solvents were eliminated under vacuum in the dark for more than 3 h.
The lipidﬁlmswere resuspended in anappropriate buffer and incubated
either at 25 °C or 10 °C above the phase transition temperature (Tm)
with intermittent vortexing for 30 min to hydrate the samples and
obtain multilamellar vesicles (MLV). The samples were frozen and
thawed ﬁve times to ensure complete homogenization and maximiza-
tion of peptide/lipid contacts with occasional vortexing. Large uni-
lamellar vesicles (LUV) with a mean diameter of 0.1 and 0.2 μm for
either leakage or lipid mixing and fusion experiments were prepared
from multilamellar vesicles by the extrusion method [24] using
polycarbonate ﬁlters with a pore size of 0.1 and 0.2 μm (Nuclepore
Corp., Cambridge, CA, USA). The phospholipid and peptide concentra-
tion were measured by methods described previously [25,26].
2.3. Membrane leakage measurement
LUVs with a mean diameter of 0.1 μm were prepared as indicated
above in buffer containing 10 mM Tris, 20 mMNaCl, pH 7.4, and CF at a
concentration of 40 mM. Non-encapsulated CF was separated from the
vesicle suspension through a Sephadex G-75 ﬁltration column (Phar-
macia, Uppsala, SW, EU) eluted with buffer containing 10 mM TRIS,
100 mM NaCl, 1 mM EDTA, pH 7.4. Membrane rupture (leakage) of
intraliposomal CF was assayed by treating the probe-loaded liposomes
(ﬁnal lipid concentration, 0.125 mM) with the appropriate amounts of
peptide using a 5×5mm ﬂuorescence cuvette on a Varian Cary Eclipse
spectroﬂuorometer , stabilized at 25 °Cwith the appropriate amounts of
peptide, eachcuvette containingaﬁnal volumeof400 µl. Themediumin
the cuvettes was continuously stirred to allow the rapid mixing of
peptide and vesicles. Leakage was assayed until no more change in
ﬂuorescence was obtained. The ﬂuorescence was measured using a
Varian Cary Eclipse spectroﬂuorometer. Changes in ﬂuorescence
intensity were recorded with excitation and emission wavelengths set
at 492 and 517 nm, respectively. Excitation and emission slits were set
at 5 nm. One hundred percent release was achieved by adding Triton X-
100 to the cuvette to a ﬁnal concentration of 0.5% (w/w). Fluorescence
measurements were made initially with probe-loaded liposomes,
afterwards by adding peptide solution and ﬁnally by adding Triton X-
100 to obtain 100% leakage. Leakage was quantiﬁed on a percentage
basis according to the equation %L=[(Ff−F0)*100]/(F100−F0), where
Ff is the equilibriumvalue ofﬂuorescence after peptide addition, F0 is the
initialﬂuorescence of the vesicle suspension, and F100 is theﬂuorescence
value after the addition of Triton X-100.
2.4. Phospholipid-mixing measurement
Peptide-induced vesicle lipid mixing was measured by resonance
energy transfer [27]. This assay is based on the decrease in resonance
energy transfer between two probes (NBD-PE and RhB-PE) when the
lipids of the probe-containing vesicles are allowed to mix with lipids
from vesicles lacking the probes. If both types of vesicles fuse in the
presence of the peptide, the surface density of the acceptor is reduced,
resulting in a decreased efﬁciency of resonance energy transfer which is
measured experimentally. These changes in transfer efﬁciency allow
quantitative measurements of the lipid-mixing process [31]. The
concentration of each of the ﬂuorescent probes within the liposome
membrane was 0.6mol%. LUVs with a mean diameter of 0.2μm wereprepared as described above. Labeled and unlabeled vesicles in a
proportion 1:4 were placed in a 5 mm×5 mm ﬂuorescence cuvette at a
ﬁnal lipid concentration of 100μM in a ﬁnal volume of 400μl, stabilized
at 25 °C under constant stirring. The ﬂuorescencewasmeasured using a
Varian Cary Eclipse ﬂuorescence spectrometer using 467 nm and
530 nm for excitation and emission, respectively. Excitation and
emission slits were set at 10 nm. Since labeled and unlabeled vesicles
were mixed in a proportion of 1 to 4 respectively, 100% phospholipid
mixing was estimated with a liposome preparation in which the
membrane concentration of each probe was 0.12% [28]. Phospholipid
mixingwasquantiﬁed on a percentage basis according to the equation %
PM=(Ff−F0)/(F100−F0)]⋅100, Ff being the value of ﬂuorescence
obtained15min after peptide addition to a liposomemixture containing
liposomes having 0.6% of each probe plus liposomes without any
ﬂuorescent probe, F0 the initial ﬂuorescence of the vesicles and F100 as
the ﬂuorescence value of the liposomes containing 0.12% of each probe.
It should be taken into account that the characteristic lipid ﬂip-ﬂop time
is much longer than the lipid-mixing measurement time.
2.5. Inner-monolayer phospholipid-mixing (fusion) measurement
Peptide-induced phospholipid mixing of the inner monolayer was
measured by a modiﬁcation of the resonance energy transfer method
described above [31]. LUVsprepared as abovewere treatedwith sodium
dithionite to completely reduce the NBD-labeled phospholipid located
at the outermonolayer of themembrane. Final concentration of sodium
dithionite was 100 mM (from a stock solution of 1 M dithionite in 1 M
TRIS, pH 10.0) and incubated for approximately 1h on ice in the dark.
Sodiumdithionitewas then removedby size exclusion chromatography
through a Sephadex G-75 ﬁltration column (Pharmacia, Uppsala,
Sweden) eluted with buffer containing 10 mM TRIS, 100 mM NaCl,
and 1 mM EDTA, pH 7.4. The proportion of labeled and unlabeled
vesicles, lipid concentration and other experimental conditions were
the same as indicated above for the phospholipid-mixing assay. In order
to eliminate any artifact in the measurements, for each membrane
composition zero values were obtained using the ﬂuorescent values of
innermonolayer-labeled vesicles without peptidewhereas 100% fusion
was estimatedwith vesicles containing 0.12% of each probemeasured at
the same time the samples were incubated with the peptide.
2.6. Peptide binding to vesicles
The partitioning of the peptide into the phospholipid bilayer was
monitored by the ﬂuorescence enhancement of tyrosin. Fluorescence
spectrawere recorded in a SLMAminco 8000C spectroﬂuorometerwith
excitation and emission wavelengths of 274 and 305 nm, respectively,
and 4 nm spectral bandwidths. Measurements were carried out in
20 mMHEPES, 50 mMNaCl, and EDTA 0.1 mM, pH 7.4. Intensity values
were corrected for dilution, and the scatter contribution was derived
from lipid titration of a vesicle blank. Partitioning coefﬁcients were
obtained using I/ I0=1+[(Imax/ I0−1)*((KP* [L])/([W]+KP*[L]))],
where I and I0 are the ﬁnal and the initial intensities respectively, KP is
a mole fraction partition coefﬁcient that represents the amount of
peptide in the bilayers as a fraction of the total peptide present in the
system, Imax is a variable value for the ﬂuorescence enhancement at
complete partitioning determined by ﬁtting the equation to the
experimental data, [L] is the lipid concentration, and [W] is the
concentration of water (55.3 M) [29]. The peptide concentration in
the assays was 30μM.
2.7. Fluorescence quenching of Tyr emission by water-soluble and
lipophylic probes
For acrylamide quenching assays, aliquots from a 4 M solution of
the water-soluble quencher were added to the solution-containing
peptide in the presence and absence of liposomes at a peptide/lipid
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and the scatter contribution was derived from acrylamide titration of
a vesicle blank. The datawere analyzed according to the Stern–Volmer
equation [30], F0/F=1+KSV[Q], where F0 and F represent the
ﬂuorescence intensities in the absence and the presence of the
quencher [Q], respectively, and KSV is the Stern–Volmer quenching
constant, which is a measure of the accessibility of Tyr to acrylamide.
Quenching studies with lipophylic probes were performed by
successive addition of small amounts of 5NS or 16NS in ethanol to
the samples of the peptide incubated with LUV. The ﬁnal concentra-
tion of ethanol was kept below 2.5% (v/v) to avoid any signiﬁcant
bilayer alterations. After each addition an incubation period of 15 min
was kept before the measurement. The excitation and emission
wavelengths were 274 and 305 nm, respectively. The data were
analyzed as previously described [31].
2.8. Fluorescence measurements using FPE-labeled membranes
LUVs with a mean diameter of 0.1μm were prepared in buffer
containing 10 mM TRIS–HCl, pH 7.4. The vesicles were labeled
exclusively in the outer bilayer leaﬂetwith FPE as described previously
[32]. Brieﬂy, LUVs were incubated with 0.1 mol% FPE dissolved in
ethanol (never more than 0.1% of the total aqueous volume) at 37 °C
for 1 h in the dark. Any remaining unincorporated FPEwas removed by
gel ﬁltration on a Sephadex G-25 column equilibrated with the
appropriate buffer. FPE-vesicles were stored at 4 °C until use in an
oxygen-free atmosphere. Fluorescence time courses of FPE-labeled
vesiclesweremeasured after the desired amount of peptidewas added
into 400 µl of lipid suspensions (200μM lipid) using a Varian Cary
Eclipse ﬂuorescence spectrometer. Excitation and emission wave-
lengths were set at 490 and 520 nm, respectively, using excitation and
emission slits set at 5 nm. Temperature was controlled with a
thermostatic bath at 25 °C. The contribution of light scattering to the
ﬂuorescence signals was measured in experiments without the dye
and was subtracted from the ﬂuorescence traces. The data were
analyzed as previously described [28].
2.9. Measurement of the membrane dipole potential using
di-8-ANEPPS-labeled membranes
Aliquots containing the appropriate amount of lipid in chloroform–
methanol (2:1 v/v) and di-8-ANEPPS were placed in a test tube to
obtain a probe/lipid molar ratio of 1:100 and LUVs, with a mean
diameter of 90 nm, were prepared as described previously. Steady-
state ﬂuorescence measurements were recorded with a Varian Cary
Eclipse spectroﬂuorometer. The excitation ratio, Rex, is deﬁned as the
ratio of emission intensity at 620 nm caused by excitation with 450
and 520 nm light [33]. The mechanism by which di-8-ANEPPS operate
in order to sense dipole potential is believed to be electrochromic;
absorption and emission peaks shift in response to a nearby electrical
ﬁeld that differentially interacts with the ground state and excited
state dipole moments of the chromophore [33]. Therefore di-8-
ANEPPS can be used as a ratiometric probe of dipole potential but
using an excitation ratio [34]. The lipid concentrationwas 200 µM, and
all experiments were performed at 25 °C.
2.10. FRET with DHE
Vesicles contained POPC/ESM/CHOL at a molar ratio of 50:25:25
plus variable proportions of DHE. The ratio of DHE/CHOL was 0, 0.05,
0.1, 0.17, 0.25, 0.42 and 1. The total lipid concentration was 2 mM and
the lipid-to-peptide ratio was 50:1. The suspensions containing both
peptide and lipid were incubated overnight. Fluorescence spectra
were recorded in a SLM Aminco 8000 spectroﬂuorometer with
excitation at 274 for tyrosine and emission of both tyrosine (donor)
and DHE (acceptor) were recorded between 290–500 nm. Theexperimentally determined values of FRET efﬁciency, E, were cal-
culated according to [35].
2.11. Small-angle X-ray scattering experiments
MLVs at a concentration of 5% (w/w) prepared without or with the
peptide at a lipid/peptide molar ratio of 50:1 were prepared as stated
above and submitted to 15 temperature cycles (heating at 45 °C and
coolingat−20 °C). Lipid, at a concentration of 67 mM,was resuspended
in buffer containing 20 mM HEPES, and 50 mM NaCl, pH 7.4. Small-
angle X-ray diffraction (SAXD) measurements were carried out using a
Hecus SWAX-camera (Hecus X-ray Systems, Graz, Austria) as described
previously [36] using Ni-ﬁltered Cu-Kα radiation (λ=1542 Å) origi-
nating froma sealed tubeX-raygenerator (Seifert, Alvenburg,Germany)
operating at a power of 2 kW (50 kV, 4 mA). Sample-to-detector
distance was 27.8 cm. A linear-position-sensitive detector was used
with 1024-channel resolution. SAXD angle calibration was done with
silver stearate. The measurements were performed with the sample
placed in a thin-walled 1-mm diameter quartz capillary held in a steel
cuvette holder at different temperatures with an exposure time of 1 h.
The SAXD curves were analyzed after background subtraction and
normalization in terms of a full q-range model using the program GAP
[37].
2.12. 31P NMR
Samples were prepared as described above at a lipid/peptide
molar ratio of 50:1 and concentrated by centrifugation (14,000 rpm
for 15 min). 31P NMR spectra were recorded at different temperatures
in the Fourier transform mode in a Bruker Avance 500 MHz NMR
(Bruker BioSpin) spectrometer operating at a resonance frequency of
202.38 MHz for 31P-nuclei using a 4-mm CP-MAS probe. The samples
were packed into 4-mm zirconia rotors and placed in the spinning
module of the CP-MAS probe; no spinning and no cross-polarization
were used. Probe temperature was maintained by a Bruker BVT 3000
variable digital temperature unit. Measurements, spectra acquisition,
and calibration were essentially performed as previously described
[38]. MAS 31P NMR spectra were obtained using a Bruker 4-mm CP-
MAS probe without cross-polarization. The spinning speed was 9 kHz,
regulated to 3 Hz by a Bruker pneumatic unit and the temperature
was 25 °C. Measurements, spectra acquisition and calibration were
essentially performed as previously described [17]. A single 31P 90°
pulse, typically of 4μs, was used for excitation, a gated broadband
decoupling of 10 W, 32 k data points, 1600 transients and 5 s delay
time between acquisitions.
2.13. Hydrophobic moment, hydrophobicity and interfacial
hydrophobicity
Hydrophobic moment, hydrophobicity and interfacial hydropho-
bicity values were obtained from [39–41]. Two-dimensional plots of
the hydrophobic moments, hydrophobicity and interfacial hydropho-
bicity have been obtained using a window of seven amino acids,
taking into consideration the arrangement of the amino acids in the
space assuming an α-helical structure [42]. Positive values represent
positive bilayer-to-water transfer free-energy values and therefore,
i.e., the higher the value, the greater the probability to interact with
the membrane surface and/or the hydrophobic core.
3. Results
The HCV E1 envelope glycoprotein is thought to be responsible for
the membrane fusion process whereas the HCV E2 envelope glycopro-
tein is thought to mediate the binding to the host cell, although other
roles could not be ruled out [7,11,43]. Several hydrophobic patches have
been identiﬁed in both theE1andE2proteinswhichmight be important
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present the analysis of the hydrophobic moment, hydrophobicity and
interfacial hydrophobicity distribution along the E1 envelope glycopro-
tein sequence of HCV (strain 1B4J) assuming it forms anα-helicalwheel
along the whole sequence [19]. This analysis renders the potential
surface zones that could be implicated in the modulation of membrane
binding and/or protein interaction. As depicted in Fig. 1, the sequence
comprising residues 274–291 is one of the most membranotropic
regions of HCV E1 [19] and probably this segment participates in the
viral fusion process [11]. For this reason we studied the interaction of
E1FP, a peptide which comprises the residues 274–291 of this region,
with model membranes. In particular, we have focused on the binding
and interaction of E1FP with lipid bilayers, the changes induced in both
the peptide and phospholipid molecules upon membrane binding, as
well as the ability tomodulatemembranepolymorphism. Sincewehave
previously shown that peptide 274–291 did not show any signiﬁcant
difference on membrane rupture at either neutral or acidic pH [19], we
have performed all the assays at neutral pH.
The interaction of the E1FP peptide with membrane vesicles was
followedby the changeof theﬂuorescenceemissionof the Tyr residue in
the presence of model membranes [44]. It is important to note that
membrane fusion in HCV pseudo-particles does not require any protein
or receptor at themembrane surface. Fusion is additionally enhanced by
the presence of CHOL [7,45]. The quantum yield of a Tyr residue of a
peptide or proteinnormally changeswhen this amino acid is located in a
hydrophobic environment such as a phospholipid membrane, typically
leading to an increase of theﬂuorescence emission intensity. In solution,
the E1FP peptide exhibited absorption and emission maxima at 274 and
304 nm, respectively. The shape and wavelength maximum of the
spectra in solution and in the presence of membranes were similar.
However, the intensity increased signiﬁcantly in the presence of
membrane vesicles, indicating that the Tyr residue of the peptide was
in a hydrophobic environment (Fig. 2A). In the presence of EPC/CHOL
the increase in the intensity was signiﬁcantly higher than in the
presence of vesicles containing either complex lipids such as LV or
negatively-charged phospholipid mixtures like BPS/CHOL, EPA/CHOL
and EPG/CHOL (all binary lipid compositions had a molar ratio of 5:1)
(Fig. 2A). This approach allowed us to obtain the peptide partition
coefﬁcient, KP, which gave values in the range 107 for EPC/CHOL
containing liposomes and in the range 105 for the other ones. These KP
values are consistent with the tenet that the peptide binds with high
afﬁnity to the membrane surface [38,44,46,47].
We have also used the electrostatic surface potential probe FPE [48]
to analyze the binding of the E1FP peptide to model membranes
(Fig. 2B). As observed in the ﬁgure, E1FP had a higher afﬁnity for model
membranes containing LV and the system BPS/CHOL, i.e., the smallest
dissociation constant was found in the presence of these vesicles. In
contrast, the lower afﬁnity was found for the system EPG/CHOL. Being
both BPS and EPG negatively-charged phospholipids, it is interesting to
note that phosphatidylserine is the most abundant negatively-charged
phospholipid in the viral and host-cell membranes and is further
involved in lamellar to non-lamellar transitions [49]. In all cases thedata
could be adjusted to a binding proﬁle having either a sigmoidal (Hill
coefﬁcient of approximately 1) or a hyperbolic dependence (data not
shown)whichmight suggest that the interactionof the peptidewith the
membrane was monomeric.Fig. 2. (A) Determination of the partition constant, KP, of E1FP through the change of the
intrinsic tyrosine ﬂuorescence in the presence of increasing lipid concentrations,
(B) determination of the dissociation constant, Kd, of E1FP through the change of FPE
ﬂuorescence in the presence of increasing lipid concentrations and (C) effect of E1FP on
the membrane dipole potential monitored through the ﬂuorescence ratio (Rex) of di-8-
ANEPPS. LUVs were composed of EPC/CHOL at a molar ratio of 5:1 (○), BPS/CHOL at a
molar ratio of 5:1 (⋄), EPG/CHOL at a molar ratio of 5:1 (☆), EPA/CHOL at a molar ratio
of 5:1 (△) and liver extract lipids (□). Vertical bars indicate standard deviations of the
mean of triplicate samples.
2188 A.J. Pérez-Berná et al. / Biochimica et Biophysica Acta 1788 (2009) 2183–2193Changes in themagnitude of themembrane dipole potential elicited
by E1FP were monitored by the spectral shift of the ﬂuorescence probe
di-8-ANEPPS [28]. The variation of the normalized ﬂuorescence
intensity ratio R450/520 as a function of the peptide concentration for
different membrane compositions is shown in Fig. 2C. The data
demonstrate that the peptide was capable of inserting into the lipid
bilayer, leading to a modiﬁcation of its dipole potential. The binding of
the peptide to the membrane could be described by a saturable binding
model where the peptide increased the magnitude of the dipole
potential of all the phospholipid bilayers. In the presence of the peptide,
the strongest decrease in the R450/520 value was obtained in bilayers
containing EPC/CHOL and BPS/CHOL.
We also studied the accessibility of the Tyr residue of E1FP towards
acrylamide, a neutral, water-soluble, highly efﬁcient quenching mole-
cule, which is unable to penetrate into the hydrophobic core of the lipid
bilayer. Stern–Volmer plots for the quenching of Tyr by acrylamide are
shown in Fig. 3A. The plots are linear with a unitary intercept showing
that the Stern–Volmer dynamic quenching formalism accurately
describes the data. In aqueous solution the Tyr residue was highlyFig. 3. (A) Stern–Volmer plots of the quenching of the tyrosine ﬂuorescence emission of
E1FP by acrylamide and (B) depth-dependent quenching of the tyrosine ﬂuorescence
emission of E1FP by 5NS (ﬁlled symbols) and 16NS (empty symbols) in LUVs. LUVs were
composed of EPC/CHOL at a molar ratio of 5:1 (○,●), BPS/CHOL at a molar ratio of 5:1
(⋄,♦), EPG/CHOL at a molar ratio of 5:1 (☆,★), EPA/CHOL at a molar ratio of 5:1 (△,▲)
and liver extract lipids (□,▪). Peptide in buffer is represented as ( ) in (A).exposed to the solvent that led to amore efﬁcient quenching. The lower
KSV values obtained in the presence of lipids compared with the higher
ones in their absence, suggest that the peptide is buried in the
membrane, becoming less accessible for quenching by acrylamide.
Interestingly, the KSV values in the presence of EPC/CHOL and LV
containing vesicles were greater than in the presence of negatively-
chargedphospholipids, indicating that thepeptidewouldbe located less
deeply inside themembrane in the presence of the later phospholipids.
The transverse location of E1FP into the lipid bilayer was evaluated
by monitoring the relative quenching of the ﬂuorescence of the Tyr
residue by the lipophylic spin probes 5NS and 16NS (Fig. 3B). For 5NS
and 16NS, the nitroxide groups are located at about 12 Å and at 3 Å
from the bilayer centre [50], so that the direct comparison of the
Stern–Volmer plots provides a qualitative method to determine the
penetration of the peptide within the bilayer. In general, the peptide
was quenched more efﬁciently by 5NS than by 16NS, suggesting that
the peptide remained close to the lipid/water interface. However, the
most efﬁcient quenching takes place in membranes composed of EPC/
CHOL and LV, indicating that the location of the peptide in the
presence of the zwitterionic lipids is deeper than in the presence of
negatively-charged phospholipids.
To examine the effect of E1FP in the destabilization of membrane
vesicles, we have studied its effect on membrane rupture, i.e., leakage
(Fig. 4A). The peptide induced a signiﬁcant, dose-dependent, leakage
effect in all membrane systems studied (at the highest peptide to lipid
ratio studied, i.e., 1:5, leakage values were about 95–100%). However,
the highest leakage effect was observed for liposomes composed of a LV
(Fig. 4A). This data shows that all thesemembranes are perturbedby the
E1FP peptide at all lipid/peptide ratios tested.Membrane perturbation is
not sufﬁcient to complete the process of membrane fusion, but also the
merging of the monolayers and the stalk formation [22]. Therefore, we
have also studied the effect of the peptide on both phospholipid mixing
and fusion using a probe dilution assay [27,51]. As shown in Fig. 4B
and C, the higher phospholipidmixing and fusion valueswere found for
liposomes containing either EPC/CHOL or LV (about 95–100% phos-
pholipid mixing and 80–100% fusion at a peptide to lipid ratio of 1:5),
whereas BPS/CHOL, EPG/CHOL and EPA/CHOL displayed lower but also
signiﬁcant values (about 40% phospholipid mixing and 35% fusion at a
peptide to lipid ratio of 1:5). Therefore, the lower phospholipid mixing
and fusion values were found for liposomes containing negatively-
charged phospholipids.
The presence of both sphingomyelin and CHOL has been related to
the occurrence of laterally segregated membrane microdomains or
“lipid rafts”. Interestingly, it has been found for several viruses that
there is an important relationship between membrane fusion and the
presence of CHOL and sphingomyelin in membranes [52]. In this
context, it is further interesting to note that the presence of CHOL has
been recently reported to facilitate the fusion of HCVpp with the target
membrane [53]. Therefore, we have tested the possibility that CHOL
could mediate the interaction of the E1FP peptide with the membrane.
Since the energetic barrier for hemifusion is larger than leakage [45],
we have chosen lipid mixing to study the possible dependence of E1FP
with CHOL. The extent of phospholipid mixing for a number of
different POPC/ESM/CHOL compositions at different lipid-to-peptide
ratios is shown in Fig. 5A. Signiﬁcantly, at relatively low lipid/peptide
ratios, the higher the CHOL content, the higher the mixing. The
dependence of leakage on the molar ratio of each component in the
mixture is shown in Fig. 5B. It is readily observed that an increase of
the EPC molar ratio leads to a decrease of lipid mixing. In contrast, the
content of CHOL correlates directly with an increase of lipid mixing.
No pattern can be discerned by changing the molar ratio of ESM
(Fig. 5B). These results show that the content of CHOL in the sample is
critical for lipid mixing. Probably E1FP interacts speciﬁcally with CHOL
and/or its effects exerted on membranes depend on its presence. A
representation of all studied POPC/ESM/CHOL compositions is shown
as a ternary phase diagram in the insert of Fig. 5A. Since this ternary
Fig. 4. Effect of E1FP on (A) membrane rupture, i.e., leakage, (B) membrane
phospholipid mixing of the outer monolayer, i.e., lipid mixing, and (C) membrane
phospholipid mixing of the inner monolayer, i.e., fusion, of ﬂuorescent probes
encapsulated in LUVs containing different lipid compositions at different lipid-to-
peptide molar ratios. LUVs were composed of EPC/CHOL at a molar ratio of 5:1 (○),
BPS/CHOL at a molar ratio of 5:1 (⋄), EPG/CHOL at a molar ratio of 5:1 (☆), EPA/
CHOL at a molar ratio of 5:1 (△) and liver extract lipids (□).
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studied here would have a coexistence of liquid-ordered and liquid-
disordered phases, i.e., a high probability of lipid raft domains. It can
be also observed that the maximum phospholipid mixing should be
obtained at a theoretical lipid composition consisting of about 80%
CHOL and about 20% ESM (dotted lines, insert of Fig. 5A). To further
conﬁrm the adsorption of E1FP to CHOL inmembranes, we have used a
ﬂuorescence resonance energy transfer between the ﬂuorescent
cholesterol analogue, dehydroergosterol (acceptor) and Tyr (donor)
[59] using LUVs of POPC/ESM/(CHOL/DHE) at a molar ratio of 2:1:1containing different DHE concentrations. As shown in Fig. 5C, an
increase in energy transfer efﬁciency with increasing DHE con-
centration, higher than the expected on the basis random distribution,
was observed. Therefore, the Tyr residue of the E1FP peptidewas in the
vicinity of DHE, i.e., adsorption occurred.
Information on the structural organization of a mixture containing
POPC/ESM/CHOL at a molar ratio of 5:1:1 in the absence and in the
presence of the E1FP peptide was studied by small-angle X-ray
diffraction, SAXD (Fig. 6A). This technique deﬁnes the macroscopic
structure and provides the interlamellar repeat distance in the
lamellar phase which comprises both the bilayer and the water
layer thickness. The structural results from the global data analysis are
shown in the insert of Fig. 6A. Both in the absence and in the presence
of the peptide, the diffraction pattern corresponded to the liquid–
crystalline Lα phase, showing an interlamellar repeat distance of
67.9 Å for the pure lipidmixture and 70.5 Å in the presence of peptide.
The membrane thickness decreased from 43.3 Å in the absence of the
peptide to 39.5 Å in its presence. However the thickness of the water
layer increased from 24.6 Å to 31.0 Å under the same conditions.
Visually, the most signiﬁcant effect was the increase of the diffuse
scattering in the presence of the peptide indicating that several
bilayers have become positional uncorrelated due to its inﬂuence.
Since the 31P NMR isotropic chemical shifts of both ESM and POPC
headgroups are resolvable under MAS NMR conditions, we have used
31P MAS NMR for observing the mixture POPC/ESM/CHOL at a molar
ratio of 5:1:1 in the absence and in the presence of the E1FP peptide. As
observed in Fig. 6B, the chemical shift for the POPC and ESM resonances
was not different neither in the absence nor in the presence of the
peptide, but the linewidths of the 31P resonances of POPC and ESMwere
dissimilar. In the absence of the peptide, the 31P line widths at half
height were 42.5 Hz and 51 Hz for POPC and ESM respectively, whereas
they shifted to 70.4 Hz and 109.9 Hz for POPC and ESM respectively
when the peptide was present. These results show that both
phospholipids, POPC and ESM, exhibit a lower degree of mobility and/
or an increased heterogeneity of headgroup environments in the
presence of the peptide. However, ESM showed a higher increase in
width at half height than POPC.
Phosphatidylethanolamines in general and DEPE in particular
display a gel-to-liquid crystalline phase transition, Lβ–Lα, and a
lamellar-to-inverted hexagonal phase transition, Lα–HII. Information
on the structural organization of DEPE and DEPE in the presence of
peptide was obtained also by SAXD. The diffraction patterns of pure
DEPE andDEPE in the presence of the peptide from25° to 80° are shown
in Fig. 7A and B, respectively. Between 25 °C and 60 °C the diffraction
patternsof pureDEPEwere characteristic of the lamellar phase,whereas
at higher temperatures the hexagonal phase was detected. In the
presence of the peptide, a coexistence of gel and liquid–crystalline
phaseswas apparent at 35 °C (Fig. 7B). At 60 °C reﬂections characteristic
of the hexagonal phase appeared with a residual refraction of the
lamellar phase at higher temperatures (Fig. 7B). Thus, E1FP leads to an
increase of both transition widths.
DEPE when organized in bilayer structures gives rise to an asym-
metrical 31P NMR line-shape with a high-ﬁeld peak and a low-ﬁeld
shoulder, presenting a residual chemical shift anisotropy, Δσ, of 36–
40 ppm in the gel state and 27–30 ppm in the liquid–crystalline state
[55]. In the HII phase the chemical shift anisotropy is further averaged
due to rapid lateral diffusion of the phospholipid around the tubes of
which this phase is composed, resulting in a line-shape with reverse
symmetry, i.e., a high-ﬁeld shoulder and a low-ﬁeld peak, accompanied
by a twofold reduction in the absolute valueofΔσ. Thiswas thebehavior
we found for pure DEPE as expected (Fig. 7C). However, when E1FP was
added to attain a lipid/peptide molar ratio of 50:1, the NMR proﬁle of
DEPEwasdifferent, since, beginning at approximately 55 °C, an isotropic
peak at 0 ppm was apparent, and signiﬁcantly, a mixture of both
lamellar and hexagonal phases was observed at 60 °C, in concordance
with the SAXD data shown above (Fig. 7D).
Fig. 5. (A) Effect of E1FP on phospholipid mixing of LUVs composed of POPC/ESM/CHOL at lipid molar ratios of: 14:5:1 (◁), 5:1:1 (□), 2:1:1 (▷), 8:5:1 ( ), 26:9:15 (○), 8:5:4 (☆),
8:5:7 (⋄), 10:5:7 ( ), 1:1:1 (△), 6:5:9 (▽), and 8:5:11 ( ). The insert shows the different POPC/ESM/CHOL ratios displayed in a ternary phase diagram. (B) Dependence of
phospholipid mixing with themolar percentage of POPC, ESM and CHOL for LUVs composed of POPC/ESM/CHOL at lipid/peptide ratios of 5:1 (□), 10:1 (○) and 15:1 (△). (C) Energy
transfer efﬁciency from the Tyr residue of E1FP to DHE (acceptor) in POPC/ESM/CHOL vesicles at a molar ratio of 2:1:1 (□) and energy transfer efﬁciency expected for a random
distribution using w1=10 Å and w2=30 Å (○) and w1=5 Å and w2=25 Å (Δ) (see ref. [35]).
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Envelope fusion class I and class II glycoproteins, located on theouter
surface of the viral membranes, mediate the fusion of the viral and
cellular membranes [56,57]. Signiﬁcantly, class I and class II membrane
fusion proteins share structural and functional characteristics in speciﬁc
domainswhich interact with and disrupt biologicalmembranes [12,56–
58]. It is known that both HCV E1 and E2 envelope glycoproteins areessential for receptor binding, host-cell entry and membrane fusion;
however, their speciﬁc roles in the different processes of the viral life
cycle are not known [9,11,43,59,60]. Moreover, membrane fusion does
not necessarily occur at the plasmamembrane level; viral entry can also
involve endocytosis and vesicular trafﬁcking, as it happens in the case of
HCV. The E1/E2 heterodimer is thought to be the functional fusion unit,
capable of juxtaposing, destabilizing and merging the viral and cellular
membranes so that a fusion-pore is formed. Low-pH would induce its
Fig. 6. (A) Small-angle X-ray scattering of an EPC/ESM/CHOL MLV suspension at a molar ratio of 5:1:1 in the absence (○) and in the presence of the E1FP peptide (●). Solid lines
represent the best ﬁt to the SAXD data applying a global analysis technique. The insert displays the one dimensional electron density proﬁles along the bilayer normal calculated from
the SAXD diffraction patterns in the absence (····) and in the presence of the peptide (――). Panel (B) showsMAS 31P NMR spectra of an EPC/ESM/CHOLMLV suspension at a molar
ratio of 5:1:1 in the absence (····) and in the presence (――) of the E1FP peptide at a phospholipid/peptide molar ratio of 50:1. The 31P NMR spectra have been normalized. Data was
obtained at 25 ºC.
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fusion protein [11,60–62]. Several hydrophobic segments have been
identiﬁed in both E1 and E2 envelope glycoproteins which might be
important in the mechanism of membrane fusion, not only for
modulating membrane binding and interaction, but also for protein–
protein interaction [15,16,19,43,63]. These segments bind and destabi-
lize the biological membrane, and these interactions should be decisive
formembrane fusion. In thisworkwehave characterized the interaction
of E1FP, a peptide derived fromone of themostmembranotropic regions
the HCV E1 glycoprotein (amino acids 274–291), with model mem-
branes. This study provides new evidence for the functional role of this
region in the membrane fusion mechanism of HCV.
E1FP bindswith high afﬁnity to different types of phospholipidmodel
membranes. Themain binding force is apparently of hydrophobic origin,
most likely due to the high hydrophobicity and interfacial hydrophobic-
ity values shown in the peptide sequence (Fig. 1). After binding, the
peptide decreased the dipole potential of the membrane. Even though
the Tyr residue is located in the N-terminal part of E1FP, we have been
able to study the binding of the peptide to membrane vesicles by
hydrophilic and lipophilic quenching probes. E1FP was less accessible for
quenching by acrylamide in the presence of zwitterionic and complex
phospholipids than in thepresenceofnegatively-containingmembranes,
implying a buried location in the former compositions. Similar results
were obtained in the presence of NS probes, since a higher quenching
efﬁciency was observed for model membranes containing zwitterionic
and complex phospholipids (i.e., liver lipid extract). Nevertheless, the
peptide was capable of binding with high afﬁnity to model membranes
containing both negatively-charged and zwitterionic phospholipids and
it was located near the membrane lipid/water interface.
E1FP disrupted the membrane causing the release of ﬂuorescent
probes. This effect was found to depend on lipid composition and on the
lipid/peptide molar ratio. The highest effect was observed for liposomes
containing a complex mixture of phospholipids, but lower although
signiﬁcant leakage valueswere also observed for liposomes composed of
zwitterionic and negatively-charged phospholipids. The induction of
lipidmixingand fusionbyE1FPwere also studiedandsimilar resultswere
obtained, since speciﬁc and large membrane lipid mixing and fusion
values were found in the presence of liposomes composed of complex,
negatively-charged and zwitterionic phospholipids. Membrane rupture
by E1FP is therefore mainly due to hydrophobic interactions within the
bilayer; however, the charge of the phospholipid headgroups also affects
to some extent membrane leakage. Interestingly, the presence of CHOLhas recently been described to facilitate the fusion with the target
membrane of HCVpp [53].We demonstrate here that CHOL indeed is one
of themajor determinants of the effects producedby E1FP onmembranes
since it speciﬁcally interacts with CHOL and its effect depends on the
molar ratio of this molecule. Even so, the presence of raft domains could
be also decisive for the biological function of the protein region where
the E1FP peptide resides.
Moreover, the presence of E1FP decreased membrane thickness and
increased its hydration layer and at the same time induced the presence
of positionally uncorrelated bilayers.Membrane thinning is a frequently
found response of lipid bilayers to binding of peptides [64], but not
necessarily a universal behavior [65]. It can be understood as the
formation by the surface adsorbed peptide of a local dimple [66] that
leads to a global decrease of the bilayer thickness. This effect will lead to
an overall decrease of the bending rigidity, which facilitates fusion by
reducing the free-energy barriers for passing through highly curved
intermediate states [67]. Indeed, the increase of the water layer, as well
as the partial loss of positional correlations between adjacent bilayers
indicate membrane softening, driving some of the stacked bilayers into
an unbound state [68,69]. Additionally, the phosphate groups of the
phospholipid molecules displayed a lower degree of mobility and/or an
increased heterogeneity of headgroup environments in the presence of
E1FP. This result strengthens that the location of the peptide is at or near
the membrane interface. Interestingly, E1FP changed the polymorphic
phase behavior of themembranes, since it induced the presence of anHII
phase at slightly lower temperatures than in pure DEPE bilayers.
In conclusion, E1FP was able to affect the elastic and structural
properties of lipid bilayers, leading to a signiﬁcant effect on both
membrane fusion and leakage, which also depended upon the
concentration of CHOL [53]. These effects are possibly related to the
conformational changes which might occur on E1 glycoprotein during
the fusion process. As it has been suggested previously, the E1 region
where E1FP residesmight have an essential role in themembrane fusion
process, as it has been observed for other analogous proteins (i.e., HIV
gp41). In principle only peptides affecting the lipid polymorphic phase
behavior could be located in regions implicated in a stabilization/
destabilization role of lamellar/non-lamellar structures, the role needed
for membrane fusion. Furthermore, E1FP would interact with the
membrane through both electrostatic and hydrophobic effects, leading
to an adsorption to the membrane interface. It is known that several
fusion peptide fragments are prone to promote the formation of local
nipples in the cellmembrane leading to the formationof local bends and
Fig. 7. (A,B) Small-angle X-ray scattering patterns and (C,D) static 31P NMR spectra of DEPE phospholipid dispersions in the absence (A,C) and in the presence (B,D) of the E1FP
peptide at a phospholipid/peptide molar ratio of 50:1 at different temperatures as stated. The 31P NMR spectra have been normalized.
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Therefore, this implies that both HCV E1 and E2 glycoproteins are
directly involved in the mechanism that facilitates the entry of the HCV
virus into its cellular host. Whereas other membranotropic segments
would be implicated in membrane destabilization, pore formation and
enlargement, fusion peptides from both E1 and E2 would be of
importance in the very ﬁrst steps of membrane fusion.
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